Literature DB >> 20402558

Treatment of HIV infection with the CCR5 antagonist maraviroc.

Wiete Kromdijk1, Alwin D R Huitema, Jan Willem Mulder.   

Abstract

IMPORTANCE OF THE FIELD: The emergence of resistance in treatment-experienced HIV patients often limits therapeutic success of the currently available antiretroviral drugs. New drug classes are thus required. Maraviroc is the first chemokine receptor 5 antagonist approved for use in treatment experienced HIV patients with a R5-tropic virus. AREAS COVERED IN THIS REVIEW: For this review, data from pharmacokinetic, Phase II and III clinical trials were reviewed. WHAT THE READER WILL GAIN: The objectives of this review were to discuss the pharmacokinetics and clinical efficacy and safety of maraviroc in treatment-experienced and -naive HIV patients with R5-tropic virus. Additionally, tropism testing was discussed. TAKE HOME MESSAGE: Maraviroc is effective in previously treated patients with R5-tropic virus only. Also, maraviroc will be an attractive option for HIV-1-infected treatment-naive patients with R5-tropic viruses only, once genotypic assays have been validated.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20402558     DOI： 10.1517/14656561003801081

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


  14 in total

1.  In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.

Authors:  Zhonghua Liu; Mei Shan; Li Li; Lu Lu; Shu Meng; Cheng Chen; Yuxian He; Shibo Jiang; Linqi Zhang
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

Review 2.  Physiology and pharmacology of plerixafor.

Authors:  Simon P Fricker
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

3.  Getting pharmaceutical R&D back on target.

Authors:  Mark E Bunnage
Journal:  Nat Chem Biol       Date:  2011-06       Impact factor: 15.040

4.  Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.

Authors:  Joshua F Emory; Lauren A Seserko; Mark A Marzinke
Journal:  Clin Chim Acta       Date:  2014-02-19       Impact factor: 3.786

5.  Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.

Authors:  Arangassery Rosemary Bastian; Aakansha Nangarlia; Lauren D Bailey; Andrew Holmes; R Venkat Kalyana Sundaram; Charles Ang; Diogo R M Moreira; Kevin Freedman; Caitlin Duffy; Mark Contarino; Cameron Abrams; Michael Root; Irwin Chaiken
Journal:  J Biol Chem       Date:  2014-11-04       Impact factor: 5.157

6.  Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.

Authors:  Gloria Lau; Jean Labrecque; Markus Metz; Roy Vaz; Simon P Fricker
Journal:  J Biol Chem       Date:  2015-03-12       Impact factor: 5.157

7.  Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.

Authors:  Julia Gavrilyuk; Hitoshi Ban; Hisatoshi Uehara; Shannon J Sirk; Karen Saye-Francisco; Angelica Cuevas; Elise Zablowsky; Avinash Oza; Michael S Seaman; Dennis R Burton; Carlos F Barbas
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

8.  Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors.

Authors:  Xiaoling Yu; Lin Yuan; Yang Huang; Weisi Xu; Zhiming Fang; Shuwen Liu; Yiming Shao; Shibo Jiang; Liying Ma
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

9.  Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.

Authors:  C Preston Neff; Thomas Ndolo; Apurva Tandon; Yuichiro Habu; Ramesh Akkina
Journal:  PLoS One       Date:  2010-12-21       Impact factor: 3.240

10.  A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.

Authors:  C Preston Neff; Theresa Kurisu; Thomas Ndolo; Kami Fox; Ramesh Akkina
Journal:  PLoS One       Date:  2011-06-01       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.